全文获取类型
收费全文 | 631篇 |
免费 | 34篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 29篇 |
妇产科学 | 5篇 |
基础医学 | 56篇 |
口腔科学 | 2篇 |
临床医学 | 64篇 |
内科学 | 181篇 |
皮肤病学 | 8篇 |
神经病学 | 52篇 |
特种医学 | 16篇 |
外科学 | 56篇 |
综合类 | 8篇 |
一般理论 | 3篇 |
预防医学 | 35篇 |
眼科学 | 13篇 |
药学 | 59篇 |
肿瘤学 | 81篇 |
出版年
2023年 | 11篇 |
2022年 | 16篇 |
2021年 | 30篇 |
2020年 | 17篇 |
2019年 | 13篇 |
2018年 | 14篇 |
2017年 | 16篇 |
2016年 | 18篇 |
2015年 | 20篇 |
2014年 | 28篇 |
2013年 | 24篇 |
2012年 | 35篇 |
2011年 | 39篇 |
2010年 | 16篇 |
2009年 | 26篇 |
2008年 | 28篇 |
2007年 | 31篇 |
2006年 | 34篇 |
2005年 | 25篇 |
2004年 | 16篇 |
2003年 | 16篇 |
2002年 | 11篇 |
2001年 | 15篇 |
2000年 | 7篇 |
1999年 | 8篇 |
1997年 | 3篇 |
1996年 | 6篇 |
1995年 | 6篇 |
1994年 | 3篇 |
1992年 | 12篇 |
1991年 | 7篇 |
1990年 | 5篇 |
1989年 | 14篇 |
1988年 | 6篇 |
1987年 | 7篇 |
1986年 | 14篇 |
1985年 | 4篇 |
1984年 | 6篇 |
1983年 | 3篇 |
1982年 | 5篇 |
1979年 | 11篇 |
1978年 | 8篇 |
1977年 | 2篇 |
1975年 | 2篇 |
1974年 | 14篇 |
1973年 | 3篇 |
1972年 | 5篇 |
1971年 | 3篇 |
1969年 | 1篇 |
1968年 | 2篇 |
排序方式: 共有670条查询结果,搜索用时 31 毫秒
91.
P Carde J M Burgers M van Glabbeke M Hayat J M Cosset R Somers W Sizoo M M Qasim R Lefur J S Abbatucci 《Radiotherapy and oncology》1984,2(4):301-312
Patients with stage I and II non-Hodgkin's lymphoma (NHL) are considered to have a relatively good prognosis. For this reason, they are seldom referred to specialized centers and the accrual of such patients in controlled studies is limited. Therefore, significant studies of homogeneously treated patients are difficult to collect and the management of these patients remains controversial. Some patients do very well after treatments with minimal toxicity while others require a much more aggressive approach. The Radiotherapy-Chemotherapy Group of the EORTC carried out its second controlled trial on patients with stage I and II NHL from 1975 to 1980. Its first aim was to assess the prognostic value of histologic classifications independently of treatment. The second aim was to compare two therapeutic options within each stage. In stage I, 124 patients were randomized to receive extended field radiotherapy (RT) either with or without adjuvant cyclophosphamide, vincristine prednisone (CVP) chemotherapy (CT). Relapse-free survival (RFS) was higher in patients who received adjuvant CVP but the total survival rates were not different. The RFS was lower in patients with diffuse than in those with follicular architectural histologies; in the former, RFS was not influenced by adjuvant CVP. Those patients who underwent a staging laparotomy had a higher 5-year total survival (TS) independent of the histologic type. Fifty-six stage II patients were included and extended field was randomized versus total nodal irradiation. Subsequently, adjuvant CVP was given to all patients. Results are good in follicular histologies but the advantage for total nodal irradiation is not significant. In diffuse histologies, results were unsatisfactory in both arms; a new therapeutic strategy was designed in which RT and CT are alternated and has been successfully tested in a pilot study. 相似文献
92.
J P Constans A Castresana J F Meder C Vedrenne J M Cosset M Hayat 《Bulletin du cancer》1989,76(3):301-310
Intracranial localizations of Hodgkin's disease (HD) are uncommon. We report on 2 patients with HD who presented with an intracranial relapse. We discuss 1) the pathogenesis of those rare recurrences; 2) the therapeutic strategy. 相似文献
93.
M Ghosn P Carde B Leclerq F Flamant S Friedman J P Droz M Hayat 《Bulletin du cancer》1988,75(4):391-392
A case of reversible encephalopathy after one dose of ifosfamide/mesna in an epileptic 15-year-old girl is reported. No other pathology could be responsible for the symptoms. An epilepsy or a toxicity induced by vincristine were discussed. Nevertheless, the possible role of phenobarbital, known to induce hepatic microsomal activity, seems the more probable mechanism. 相似文献
94.
M Tubiana M Henry-Amar M Hayat M Burgers M Qasim R Somers W Sizoo E van der Schueren 《International journal of radiation oncology, biology, physics》1984,10(2):197-210
Since 1964, the European Organisation for Research and Treatment of Cancer has conducted three subsequent clinical trials on clinical Stages (CS) I + II Hodgkin's disease (HD) in which 1059 patients have been entered. The first trial compared regional radiotherapy (RT) with mantle field or inverted Y, versus the same RT followed by a weekly injection of vinblastine for 2 years. The relapse free survival (RFS) and overall survival (S) were higher in patients treated by RT and chemotherapy (CT). This benefit, however, was significant only in patients with a mixed cellularity histologic type. The second trial compared the therapeutic efficacy of splenic irradiation versus splenectomy and found that in both arms, RFS and S were identical. Moreover, it was found that splenic involvement was correlated with an increased incidence of relapse in extranodal sites and in non irradiated lymphatic areas. In this trial, CT was given only to patients with poor histologic types, mixed cellularity or lymphocytic depletion. In the third trial, staging laparotomy was performed only to further delineate a good prognostic group which could be treated by RT alone. In this limited treatment group, there was no difference in RFS and S between mantle field and mantle field + para-aortic RT. In the extensive treatment group, total nodal irradiation (TNI) was compared with RT + MOPP. The RFS was slightly lower in the TNI arm, but there was no significant difference in S. The data of the 3 trials underline the importance of prognostic factors in the choice of optimal treatment and show that their significance depends upon the type of treatment. Multivariate statistical analyses showed that the main prognostic factors, which can help to identify the subsets of patients who can be treated by RT alone, are (1) systemic symptoms and elevated erythrocyte sedimentation rate (ESR), (2) the number of involved lymphatic areas, and (3) staging laparotomy. Extended RT (mantle + para-aortic + spleen treatment) gives satisfactory results in patients without systemic symptoms and/or elevated ESR and one or two involved sites, whereas TNI or combined modality treatment becomes mandatory for patients with 3 or more involved sites or splenic involvement and/or systemic symptoms. With proper adjustment of the irradiated volume, a very large proportion of CS I + II patients can be best treated by RT alone. 相似文献
95.
96.
G. Math L. Schwarzenberg J. L. Amiel P. Pouillart M. Hayat F. de Vassal C. Rosenfeld C. Jasmin 《Journal of the Royal Society of Medicine》1975,68(4):211-216
The present results of our treatment of acute lymphoid leukaemia patients are summarized: 7 out of 20 randomized patients given active immunotherapy after chemoradiotherapy are still in complete remission after periods varying from seven to ten years (compared to none in the control group). The actuarial results on 100 patients show remission and survival curves presenting a plateau between three and five years for a certain percentage, suggesting a possible cure. Several parameters studied in 200 patients indicate that the factors affecting this percentage are age, cytological type, volume of the tumour, and the localization of leukaemic cells in certain areas. Experiments with L1210 leukaemia show that immunotherapy enhances the effect of chemotherapy when administered after chemotherapy but decreases it when administered before, which is in favour of the use of the sequence chemotherapy-immunotherapy clinically. 相似文献
97.
98.
99.
D Baume J M Cosset J L Pico T Girinski N Le Bail J M Nabholtz E Benhamou J Dutreix M Hayat 《Bulletin du cancer》1988,75(4):361-372
The present study is a retrospective analysis of 54 patients with hematological malignancies who were treated by total body irradiation (TBI) and allogenic bone-marrow transplantation from 1982-1986. Patients were not randomly assigned to receive either single dose total body irradiation (STBI) (10 Gy x 1-4 cGy/min-lung dose 8 Gy) or hyperfractionated total body irradiation (HTBI) (1,20 Gy x 11-3 fractions/day-lung dose 9 Gy). Thirty one patients received STBI and 23 a HTBI regimen. Despite the presence of a large proportion of patients with a high risk of leukemic relapse in the HTBI group, the incidence of relapse did not differ significantly in the two groups: STBI (16%), HTBI (21%). Lung and liver toxicity were predominant in the STBI group. Interstitial pneumonitis occurred in 45% of the STBI patients versus 13% in the HTBI group. This difference remains significant when adjusted to the incidence of graft versus host disease (GVHD) in the two groups. Three cases of veino-occlusive disease were observed (10%), but only in the STBI group. Even when differences in age and the frequency of GVHD are considered in the two groups, these findings suggest that HTBI is at least as effective as STBI and that toxicity is reduced with this schedule. 相似文献
100.